CRISPR in Oncology: From the Era of FIXING ERRORS to the Era of DESTROYING FAULTY CELLS

RNA-Triggered Cell Destruction with Cas12a2 — First Preclinical Evidence for KRAS G12C and HPV from Nature 2026

An RNA-triggered, indiscriminate DNA shredder: what is Cas12a2?

Cas12a2 is a new clade of Type V CRISPR nucleases identified in 2023 from Sulfuricurvum and metagenomic sources. Its fundamental shared feature with earlier generations of CRISPR enzymes is being RNA-guided — that is, a short guide RNA (gRNA) directs it to a specific nucleotide sequence. Its distinguishing feature is its behavior after finding its target. The guide RNA of Cas12a2 recognizes its target RNA through ribonucleotide, not ribosomal, pairing; it becomes activated in the presence of an adenine-rich motif called the protospacer-flanking sequence (PFS). After activation, the enzyme starts indiscriminately degrading every DNA molecule it encounters — including chromosomal DNA.

The study describes this behavior as "indiscriminate dsDNase activity": shredding double-stranded DNA. This feature of Cas12a2 had already been shown to be a defense mechanism in bacteria (halting the bacterium during phage infection). What is now demonstrated is more critical: the same mechanism is active in human cells too and kills the cell.

1. Selective destruction of HPV-infected cells

The study's first clinical concept is elimination of cells carrying high-risk HPV variants (particularly HPV18 and HPV16). The rationale is this: viral E6 and E7 oncogene transcripts do not naturally occurin the human transcriptome, so a Cas12a2 RNP targeting these transcripts will trigger only the infected cell and will not disturb a healthy cell.

HPV-associated cancers are an invisible burden in global oncology: cervical, anal, vaginal, vulvar cancers, and especially oropharyngeal squamous cell carcinoma (OPSCC), which has increased rapidly over the past 20 years. Today's standard treatment remains surgery, chemoradiotherapy, and immunotherapy added in recent years; however, recurrence is common, and patients are seriously affected by long-term adverse effects. The Cas12a2 approach holds the promise of biomarker-based elimination of residual or recurrent tumor cells that retain viral RNA. German biotechnology company Akribion Therapeutics has taken this enzyme (under the trade name G-dase® E) into clinical development specifically for OPSCC; it emerged from stealth mode in February 2025 with €8 million in seed funding and is at the in vivo proof-of-concept stage.

2. Enrichment of gene-editing efficiency

The study's second application, although not directly affecting clinical oncology, is important for the gene-therapy research infrastructure. In CRISPR editing (for example, somatic correction in BRCA1 carriers or CAR-T engineering), edited cells usually make up only a small part of the population. Cas12a2, using a guide targeting the unedited original transcript, can eliminate unedited cells from the population.

Results: 3,1-fold enrichment for indels produced with FnCas12a; up to 4,3-fold enrichment for single- and double-base mutations produced by prime editing. This is a practical tool for the efficiency bottleneck in CRISPR-based cell therapies.

3. KRAS G12C: cancer cell destruction at single-nucleotide resolution

This is the study's most striking section from an oncology perspective. KRAS G12C is a single-base change (G→T) found in approximately 11–13% of lung adenocarcinomas and a small proportion of colorectal cancers: cysteine replaces glycine at codon 12. Long considered "undruggable", KRAS first became targetable in 2021 with FDA accelerated approval for sotorasib . However, median progression-free survival is only 5–6 months; resistance develops rapidly and has heterogeneous origins (secondary KRAS mutations, EMT, Wnt/β-catenin activation).

The study designed a guide targeting the KRAS G12C transcript while ignoring wild-type (WT) KRAS transcripts. Of three candidate guides, g-KRAS(2) was activated in vitro only by the mutant transcript — no DNA damage occurred with the WT transcript. Results from cell-culture experiments:

Off-target activation: an old concern for a new technology

In conventional CRISPR, the off-target concern is accidentally cutting another genomic region. For Cas12a2, the problem is different: after enzyme activation, the question is not which DNA it cuts, but whether, when activated, it recognizes a transcript the user did not intend . The study examined this issue at three levels:

• Synthetic mismatch test: Paired mismatches were tested in every region of the 21-nucleotide guide; none produced cell depletion.
• In silico genome screening: Potential off-target regions were screened with Cas-OFFinder. Of 4 candidate transcripts with two mismatches, only one caused Cas12a2 to become partially activated in vitro — and its expression level in HeLa-GFP cells was almost negligible (1 FPKM).
• RNA-seq transparency: In cells treated with a non-targeting guide, compared with the vehicle control, not a single gene was differentially expressed. By contrast, the targeting guide affected more than 800 genes.

This study has no short-term clinical impact; no patient will be treated with Cas12a2 in the coming years. However, its medium- to long-term implications can be considered at three levels:

First, a new tool for biomarker-based oncology. Today, we mostly use biomarkers for treatment eligibility : sotorasib if KRAS G12C is present, osimertinib if EGFR Δ19 is present, and a PARP inhibitor if BRCA is present. In the Cas12a2 paradigm, the biomarker instead becomes a direct trigger for killing — the biomarker both sets the direction and fires the weapon. This matters in scenarios where small-molecule targets are considered "undruggable" or resistance has developed.

Second, combination strategies. The study's most practical finding is that Cas12a2 remains active despite acquired resistance to sotorasib. This suggests a scenario beyond modern oncology's logic of "sequential monotherapy": a small molecule and RNA-triggered destruction could be given simultaneously, eliminating resistant subpopulations at the outset. However, this proposal is purely hypothetical and still far from clinical trials.

Third, in HPV-positive cancers. OPSCC has increased rapidly over the past 20 years; the scale of this increase is not yet clear in Türkiye, but clinical observation at centers such as Memorial shows a well-known year-on-year rise in HPV+ head and neck cases. Akribion's choice of HPV-induced OPSCC as the first target in its clinical development pipeline is strategic in this respect.

• Zero clinical data. All results are from in vitro experiments and mice. There are no patient data.
• The delivery problem. Cas12a2 was delivered by electroporation or intratumoral LNP. Systemic IV delivery, target-specific tropism, and long-term safety have not been demonstrated.
• Scenarios involving more than one dose. The immune system may develop antibodies against bacterially derived Cas12a2; humanized/ML-designed variants will be needed for repeat-dose scenarios.
• Off-target screening is not yet mature. Methods established for Cas9, such as GUIDE-seq and CIRCLE-seq, cannot be applied directly; dedicated off-target mapping tools for Cas12a2 need to be developed.
• Single-cell heterogeneity. In the study, the KRAS G12C-overexpressing U2OS model shows 62% destruction, but native heterozygous NCI-H23 shows 50%; low transcript levels may not fully activate Cas12a2, creating a risk of reduced efficacy in tumors with low target-gene expression.

This article is for medical news/information purposes and does not provide individual treatment guidance. Cas12a2/G-dase E remains at the preclinical research stage; it is not approved for human use and is not expected to enter routine clinical practice in the next few years. Current treatment choices for KRAS G12C-positive lung cancer and HPV-positive head and neck cancers require multidisciplinary tumor-board decisions and comprehensive genomic profiling; access to small-molecule inhibitors (sotorasib, adagrasib) in Türkiye under individual-use authorizations should be considered. Editor's note: this article is based on the study by Scholz and colleagues published on 6 May 2026 in Nature and the simultaneous press releases from University of Utah Health and Akribion Therapeutics.